Next Article in Journal
Lambda Interferons: New Cytokines with Old Functions
Next Article in Special Issue
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Previous Article in Journal
Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs
Article Menu

Export Article

Open AccessArticle
Pharmaceuticals 2010, 3(4), 782-794; doi:10.3390/ph3040782

Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics

1
Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden
2
Department of Clinical Pharmacology, Karolinska University Hospital, Huddinge C1:68, SE-141 86, Stockholm, Sweden
*
Author to whom correspondence should be addressed.
Received: 18 January 2010 / Revised: 9 March 2010 / Accepted: 22 March 2010 / Published: 24 March 2010
(This article belongs to the Special Issue Personalized Medicine)
View Full-Text   |   Download PDF [125 KB, uploaded 24 March 2010]   |  

Abstract

Increasing evidence for the role of pharmacogenetics in treatment resistance to the antiplatelet agent clopidogrel has been gained during the last years. Apart from CYP2C19 genetic polymorphisms, nongenetic factors, particularly drug-drug interactions, age and other clinical characteristics influence the interindividual variability in clopidogrel response to varying degrees. The present article reviews the so far accumulated evidence on the role of pharmacogenetic traits influencing CYP-activity as determinants of the antiplatelet response to clopidogrel, and its clinical implications. The genetic variation in CYP2C19 activity seems to influence short- and long-term antithrombotic effects of clopidogrel to a substantial extent. Prediction models for clopidogrel non-responsiveness that include CYP2C19 genotyping together with relevant non-genetic risk factors are needed to be verified for their potential benefit in individualization of antithrombotic therapy. View Full-Text
Keywords: clopidogrel; CYP2C19; antiplatelet response; pharmacogenetics clopidogrel; CYP2C19; antiplatelet response; pharmacogenetics
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Dahl, M.-L.; Gunes, A. Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics. Pharmaceuticals 2010, 3, 782-794.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top